Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

277 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Oncogenic driver mutations predict outcome in a cohort of head and neck squamous cell carcinoma (HNSCC) patients within a clinical trial.
Fernández-Mateos J, Pérez-García J, Seijas-Tamayo R, Mesía R, Rubió-Casadevall J, García-Girón C, Iglesias L, Carral Maseda A, Adansa Klain JC, Taberna M, Vazquez S, Gómez MA, Del Barco E, Ocana A, González-Sarmiento R, Cruz-Hernández JJ. Fernández-Mateos J, et al. Among authors: iglesias l. Sci Rep. 2020 Oct 6;10(1):16634. doi: 10.1038/s41598-020-72927-2. Sci Rep. 2020. PMID: 33024167 Free PMC article.
SEOM clinical guidelines for the treatment of head and neck cancer (2020).
Mesia R, Iglesias L, Lambea J, Martínez-Trufero J, Soria A, Taberna M, Trigo J, Chaves M, García-Castaño A, Cruz J. Mesia R, et al. Among authors: iglesias l. Clin Transl Oncol. 2021 May;23(5):913-921. doi: 10.1007/s12094-020-02533-1. Epub 2021 Feb 26. Clin Transl Oncol. 2021. PMID: 33635468 Free PMC article.
Long-term outcomes of induction chemotherapy followed by chemoradiotherapy vs chemoradiotherapy alone as treatment of unresectable head and neck cancer: follow-up of the Spanish Head and Neck Cancer Group (TTCC) 2503 Trial.
Hitt R, Iglesias L, López-Pousa A, Berrocal-Jaime A, Grau JJ, García-Girón C, Martínez-Trufero J, Guix M, Lambea-Sorrosal J, Del Barco-Morillo E, León-Vintró X, Cunquero-Tomas AJ, Baste N, Ocaña A, Cruz-Hernández JJ; the Spanish Head and Neck Cancer Cooperative Group (TTCC). Hitt R, et al. Among authors: iglesias l. Clin Transl Oncol. 2021 Apr;23(4):764-772. doi: 10.1007/s12094-020-02467-8. Epub 2020 Aug 14. Clin Transl Oncol. 2021. PMID: 32797376
Correction to: SEOM clinical guidelines for the treatment of head and neck cancer (2020).
Mesia R, Iglesias L, Lambea J, Martínez-Trufero J, Soria A, Taberna M, Trigo J, Chaves M, García-Castaño A, Cruz-Hernández JJ. Mesia R, et al. Among authors: iglesias l. Clin Transl Oncol. 2021 May;23(5):1001. doi: 10.1007/s12094-021-02582-0. Clin Transl Oncol. 2021. PMID: 33709222 Free PMC article. No abstract available.
Ibero-American Expert Consensus on Squamous Cell Carcinoma of the Head and Neck Treatment in Patients Unable to Receive Cisplatin: Recommendations for Clinical Practice.
Falco A, de Oliveira TB, Cacicedo J, Ospina AV, Ticona MÁ, Galindo H, Pereira MD, Aguilar-Ponce JL, Rueda-Domínguez A, Soria T, Taberna M, Iglesias L, Sowley T, Mesía R; TTCC group (Spanish Group for the Treatment of the Head and Neck Cancer). Falco A, et al. Among authors: iglesias l. Cancer Manag Res. 2021 Aug 26;13:6689-6703. doi: 10.2147/CMAR.S322411. eCollection 2021. Cancer Manag Res. 2021. PMID: 34471383 Free PMC article. Review.
Cisplatin, 5-fluorouracil, and cetuximab (PFE) with or without cilengitide in recurrent/metastatic squamous cell carcinoma of the head and neck: results of the randomized phase I/II ADVANTAGE trial (phase II part).
Vermorken JB, Peyrade F, Krauss J, Mesía R, Remenar E, Gauler TC, Keilholz U, Delord JP, Schafhausen P, Erfán J, Brümmendorf TH, Iglesias L, Bethe U, Hicking C, Clement PM. Vermorken JB, et al. Among authors: iglesias l. Ann Oncol. 2014 Mar;25(3):682-688. doi: 10.1093/annonc/mdu003. Ann Oncol. 2014. PMID: 24567516 Free PMC article. Clinical Trial.
Prospective Clinical Integration of an Amplicon-Based Next-Generation Sequencing Method to Select Advanced Non-Small-Cell Lung Cancer Patients for Genotype-Tailored Treatments.
Zugazagoitia J, Rueda D, Carrizo N, Enguita AB, Gómez-Sánchez D, Díaz-Serrano A, Jiménez E, Mérida A, Calero R, Lujan R, De Miguel E, Gámez P, Díaz-Hellín V, Nuñez JA, Iglesias L, Ferrer I, Paz-Ares L, Ponce-Aix S. Zugazagoitia J, et al. Among authors: iglesias l. Clin Lung Cancer. 2018 Jan;19(1):65-73.e7. doi: 10.1016/j.cllc.2017.06.008. Epub 2017 Jun 23. Clin Lung Cancer. 2018. PMID: 28780976
DICER1, DROSHA and miRNAs in patients with non-small cell lung cancer: implications for outcomes and histologic classification.
Díaz-García CV, Agudo-López A, Pérez C, López-Martín JA, Rodríguez-Peralto JL, de Castro J, Cortijo A, Martínez-Villanueva M, Iglesias L, García-Carbonero R, Fresno Vara JA, Gámez-Pozo A, Palacios J, Cortés-Funes H, Paz-Ares L, Agulló-Ortuño MT. Díaz-García CV, et al. Among authors: iglesias l. Carcinogenesis. 2013 May;34(5):1031-8. doi: 10.1093/carcin/bgt022. Epub 2013 Jan 24. Carcinogenesis. 2013. PMID: 23349018
Prognostic value of dual-specificity phosphatase 6 expression in non-small cell lung cancer.
Díaz-García CV, Agudo-López A, Pérez C, Prieto-García E, Iglesias L, Ponce S, Rodríguez Garzotto A, Rodríguez-Peralto JL, Cortés-Funes H, López-Martín JA, Agulló-Ortuño MT. Díaz-García CV, et al. Among authors: iglesias l. Tumour Biol. 2015 Feb;36(2):1199-206. doi: 10.1007/s13277-014-2729-8. Epub 2014 Oct 25. Tumour Biol. 2015. PMID: 25344212
277 results